TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16004778
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intensive insulin therapy)
Study: 16868064
Drug: Hydrocortisone administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administration (replacement dose)
Study: 9255748
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17 beta‐estradiol/oral sequential dydrogesterone
Study: 9255748
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol/oral sequential dydrogesterone
Study: 9255748
Drug: Oral tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tibolone
Study: 26604653
Drug: BS capsules
Normalized name: BS-001
DrugBank: BS-001 (DB17415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BS capsules containing glucoraphanin (GR) for 2 months
Study: 23164309
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus daily enemas for 2 weeks
Study: 21823381
Drug: Bupivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine infiltration of the skin and subcutaneous tissue
Study: 18655817
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of a strong-gelling sodium alginate formulation for 7 days
Study: 8786777
Drug: Gabexate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate (1 g by intravenous infusion starting 30 to 90 minutes before endoscopy and continuing for 12 hours afterward)
Study: 8786777
Drug: Placebo (mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mannitol and sodium chloride administered in the same fashion)
Study: 10655924
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution
Study: 24970272
Drug: 6% Hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethyl starch (130/0.4) + 500 ml of Ringer's lactate (HES group)
Study: 24970272
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate (1000 ml) (RL group)
Study: 15531687
Drug: Total calcium
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total calcium intake (>1767 mg/d)
Study: 15531687
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement use (>1200 mg/d)
Study: 11374604
Drug: 0 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 microg/kg intrathecal morphine (saline injection)
Study: 11374604
Drug: 2 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg/kg intrathecal morphine
Study: 11374604
Drug: 5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/kg intrathecal morphine
Study: 12660683
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 2 mg
Study: 8488994
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amiphenazole
Study: 3547126
Drug: Cyclosporine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (6 mg per kilogram of body weight per day)
Study: 30741813
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1,000 mg)
Study: 24309584
Drug: Daily language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily language rehabilitation for 2 weeks (starting 2.2 days poststroke)
Study: 24309584
Drug: Daily language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily language rehabilitation
Study: 22951346
Drug: Electrically Heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrically Heated Cigarette Smoking System (EHCSS) and EHCSS‐K3 cigarette (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Study: 19567902
Drug: High-fidelity assertive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fidelity assertive community treatment (ACT)
Study: 7522004
Drug: Both laser
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both laser treatments
Study: 10362451
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (CR, 5 g creatine monohydrate + 3 g dextrose)
Study: 10362451
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (PLA, 7 g dextrose)
Study: 29064315
Drug: Trichuris suis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichuris suis (TSO) treatment
Study: 29064315
Drug: Baseline versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline versus treatment (BVT) control
Study: 9734653
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg/kg/d)
Study: 7983237
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NM441 (20, 50, 100, 200, and 400 mg)
Study: 7983237
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of NM441 (300 mg twice daily for 6.5 days)
Study: 7983237
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NM441 (100, 200, and 400 mg)
Study: 7983237
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NM441 (400 mg)
Study: 7983237
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NM441
Study: 7983237
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of NM441
Study: 2648779
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with all three risk characteristics (no history of previous angina or myocardial infarction, ST segment elevation or signs of Q wave development, peak MB-creatine kinase value ≥ 150 IU/L)
Study: 773016
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen Quinestrol
Study: 773016
Drug: Injected drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected drug
Study: 31004346
Drug: ACT-709478 (1-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-709478 (1-400 mg)
Study: 31004346
Drug: ACT-709478 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-709478 (60 mg)
Study: 29135373
Drug: Silymarin 1,050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 1,050 mg/day
Study: 2707520
Drug: Silymarin 420
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 420 mg/day
Study: 14571350
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75 mg, could be increased to 150 mg)
Study: 14571350
Drug: Amitriptyline ER
Normalized name: amitriptyline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline ER (75 mg, could be increased to 150 mg)
Study: 1816937
Drug: Grommets inserted
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Grommets inserted as a primary treatment
Study: 24275098
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg as a tablet
Study: 24275098
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg in 10 g of granule administered directly to mouth
Study: 24275098
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg in 10 g of granule mixed with purified water
Study: 24275098
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg in 10 g of granule mixed with water containing high cation concentrations
Study: 24275098
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg in 10 g of granule mixed with milk-based infant formula
Study: 10989902
Drug: Laparoscopic skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic skills training using simulated tasks on a video-trainer for 30 minutes daily for 10 days
Study: 1463596
Drug: 70 mg/Kg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/Kg/die of reduced glutathione (GSH)
Study: 6531440
Drug: Apomorphine HCl
Normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine HCl (0.25, 0.5 or 0.75 mg sc)
Study: 6531440
Drug: Benztropine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine (2 mg iv)
Study: 31842106
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy twice a week (P2 group)
Study: 31842106
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy once a week (P1 group)
Study: 28447362
Drug: 595-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595-nm pulsed dye laser (PDL) treatment (fluence 8 J/cm3, pulse duration 10 ms, spot size 7 mm, 2 sessions every 2 weeks)
Study: 28447362
Drug: 595-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595-nm pulsed dye laser (PDL) treatment
Study: 23561694
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg microgranules
Study: 21168109
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese acupuncture (TCA) weekly for 5 weeks
Study: 21168109
Drug: Attention only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention only (practitioner present and participant supine) weekly for 5 weeks
Study: 17928991
Drug: Urate oxidase
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate oxidase (1.5 mg)
Study: 15110879
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue
Study: 9206638
Drug: Topical decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decontamination with polymyxin B, tobramycin, vancomycin and amphotericin B, and perioperative i.v. prophylaxis with cefotaxim from the day before surgery until the 7th postoperative day
Study: 9206638
Drug: Topical decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decontamination with polymyxin B, tobramycin, vancomycin and amphotericin B, and perioperative i.v. prophylaxis with cefotaxim
Study: 7959618
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH), 0.1 IU/kg/day 6 days/week for 3 years (Group A)
Study: 7959618
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and gonadotropin-releasing hormone agonist for the first 2 years (Group B)
Study: 3318430
Drug: Nabumetone 1,000
Normalized name: nabumetone 1,000 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1,000 mg given at bedtime
Study: 3318430
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg given twice daily
Study: 31396625
Drug: EPA +
Normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPA + DHA supplementation, mean dosage 1983 ± 1297 mg/d, duration 13.6 ± 6.0 weeks
Study: 24931587
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg twice daily)
Study: 17037893
Drug: G Bond
Approvals — FDA: no, EMA: no, PMDA: no
Description: G Bond (GC)
Study: 15287927
Drug: Nateglinide monotherapy
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide monotherapy (120 mg before meals) in group 1 (diet alone or low-dose sulfonylureas)
Study: 15287927
Drug: Nateglinide as
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide as add-on therapy (120 mg before meals) in group 2 (steady dose of metformin)
Study: 8795327
Drug: Diclofenac suppositories
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppositories
Study: 1505903
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (4 IU daily)
Study: 6571404
Drug: Muscle discrimination
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle discrimination training during a headache treatment program that included standard behavioral procedures.
Study: 30690638
Drug: Potent D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potent D2 antagonists
Study: 30690638
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not taking potent D2 antagonists)
Study: 20638231
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser treatment (EVL) using EVLT system
Study: 15661480
Drug: 200 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g/d of avocado (30.6 g of fat)
Study: 11836287
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg, twice a day)
Study: 10452407
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg/d in a multivitamin syrup)
Study: 106747
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray 50 microgram q.i.d.
Study: 30344071
Drug: Individual voice
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual voice therapy
Study: 15963687
Drug: Group voice
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group voice therapy
Study: 31237119
Drug: Fenofibrate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (250 mg/d)
Study: 25688781
Drug: Eliglustat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliglustat (50 or 100 mg twice daily)
Study: 21249415
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) given once daily for 3 days
Study: 21249415
Drug: Cefcapene-pivoxyl (CFPN-PI)
Normalized name: sulbactam pivoxyl
DrugBank: Sulbactam pivoxil (DB15761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefcapene-pivoxyl (CFPN-PI) divided into three daily doses for 5 days
Study: 15301653
Drug: Monthly CBASP
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly CBASP
Study: 11702804
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of alcohol (0.55 g/kg)
Study: 9627768
Drug: Triamterene/HCTZ (25/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene/HCTZ (25/12.5 mg)
Study: 7837013
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin A treatment to the ipsilateral antagonist medial rectus
Study: 3257843
Drug: Oral 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25-hydroxyvitamin D 50 micrograms/day
Study: 3257843
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral 25-hydroxyvitamin D
Study: 6990761
Drug: Oral ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ritodrine
Study: 27571777
Drug: Coaching intervention
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching intervention (leaflets and three monthly coaching sessions)
Study: 25503598
Drug: 8% Capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% Capsaicin Patch (Qutenza)
Study: 19248046
Drug: Vatalanib 1000
Normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatalanib 1000 mg twice-a-day with imatinib (400 mg/day for stratum A, 500 mg twice-a-day for stratum B) and hydroxyurea (500 mg twice daily)
Study: 17443208
Drug: Amphetamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (5 mg initially, then 10 mg for 10 subsequent doses with 3- or 4-day separations)
Study: 8851875
Drug: Bismuth citrate/amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth citrate/amoxicillin combination therapy (BIAM tablet; 250 mg amoxicillin base and 120 mg bismuth)
Study: 8851875
Drug: Bismuth citrate
Normalized name: Bismuth citrate
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth citrate monotherapy (BI tablet; 120 mg bismuth)
Study: 8851875
Drug: Bismuth citrate/amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth citrate/amoxicillin combination therapy (BIAM)
Study: 8851875
Drug: Bismuth citrate
Normalized name: Bismuth citrate
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth citrate monotherapy (BI)
Study: 1294976
Drug: Cefamandole 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 1.5 g given one hour before surgery, repeated twice eight hourly, and throughout the operation if it lasted more than three hours
Study: 1294976
Drug: Cefamandole 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 1.5 g
Study: 6202437
Drug: Prophylactic antiarrhythmic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antiarrhythmic therapy assigned to group 2 (53 patients).
Study: 28240967
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg and Placebo
Study: 15521668
Drug: Transcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous and intranasal electric stimulation of nasal muscles only (Group 1)
Study: 15521668
Drug: Surface and
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL LIQUID [Micro Guard 24 HOUR Surface and Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface and intranasal EMG biofeedback assisted specific strategies for nasal muscle education, home exercises and electric stimulation (Group 3)
Study: 8449203
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n=28)
Study: 3544935
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 mg/day) for 12 weeks
Study: 28854728
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of kisspeptin-54 (9.6 nmol/kg) administered 10 hours after the first dose.
Study: 28854728
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of kisspeptin-54 (9.6 nmol/kg) administered 36 hours prior to oocyte retrieval and followed by saline 10 hours later.
Study: 21458989
Drug: Psycho-educational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational group intervention (two weekly 6-h sessions of psycho-education and eight weekly 2-h sessions of group psychotherapy)
Study: 21458989
Drug: Patients using
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients using anti-depressive medication (both intervention and control groups)
Study: 14964334
Drug: Pulsed radio
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radio frequency energy therapy (PRFE)
Study: 14964334
Drug: PRFE placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRFE placebo treatment (sham device)
Study: 11117242
Drug: Bicarbonate/lactate peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate peritoneal dialysis solution (Bic/Lac)
Study: 11117242
Drug: Standard lactate-buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lactate-buffered peritoneal dialysis solution (Lac)
Study: 3111705
Drug: Oral etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etidronate disodium, 20 mg/kg/day
Study: 3111705
Drug: Oral etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etidronate disodium
Study: 29254887
Drug: AZD8931 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 (40 mg twice a day)
Study: 28818560
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (mean ± SD of 10.46 ± 4.63 mg/24 h, n = 17)
Study: 28818560
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (n = 17)
Study: 21173686
Drug: Midline group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midline group (intra-articular injection of 20 ml normal saline)
Study: 21173686
Drug: Lateral group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral group (intra-articular injection of 20 ml normal saline)
Study: 10977118
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus bupivacaine (Group A)
Study: 10977118
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (Group B)
Study: 2362952
Drug: Sulpiride 800
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 800 mg
Study: 2362952
Drug: Sulpiride 1200
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 1200 mg
Study: 20457702
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment
Study: 31418851
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy in Down syndrome
Study: 31418851
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy in Down syndrome